Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
IQV · against 65 other Healthcare companies of similar size
Ranked #31 of 66 · scores higher than 54% of peers
Bars: peers in each 10-point band of the valuation score14 peers with a valuation score of 60–69, including IQV · Click a bar to see the companies
Mainly thanks to its free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | IQV | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 62 reported | 3.1% | 3.0% | 52% | 30% | |
| EBITDA yieldHigher is better · 67 reported | 5.3% | 6.2% | 42% | 50% | |
| Free cash flow yieldHigher is better · 48 reported | 5.1% | 3.6% | 79% | 20% | |
| Book yieldHigher is better · 62 reported | 14.3% | 22.2% | 23% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 2 | 78.1B USD | 89 | 60 | |
| 3 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 4 | 45.9B USD | 84 | 61 | |
| 5 | 34.3B USD | 83 | 57 | |
| 26 | 193.6B HKD (≈$24.8B) | 64 | 78 | |
| 26 | 50.2B USD | 64 | 49 | |
| 29 | 28.7B USD | 63 | 52 | |
| 30 | 36.8B USD | 61 | 46 | |
| 31 | 43.2B USD | 60 | 45 | |
| 32 | 35.0B USD | 59 | 52 | |
| 33 | 58.6B USD | 58 | 52 | |
| 34 | 8.24T JPY (≈$56.0B) | 57 | 75 | |
| 34 | 54.0B USD | 57 | 47 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score